摘要
背景与目的CD44v6的过度表达与人类多种恶性肿瘤的发生、发展和转移密切相关。本研究旨在观察CD44v6在非小细胞肺癌中的表达及其在患者预后判定中的作用。方法采用RTPCR和免疫组化法,对52例非小细胞肺癌患者手术标本进行CD44v6检测,并随访。结果免疫组化法和RTPCR法测得52例肺癌组织中CD44v6阳性表达率分别为69.2%和75.0%。低分化肺癌组织中CD44v6阳性表达率显著高于高分化和中分化肺癌(P<0.05),有淋巴结转移者显著高于无淋巴结转移者(P<0.01),Ⅲ期显著高于Ⅰ期和Ⅱ期(P<0.05)。CD44v6阴性表达者生存率显著高于CD44v6阳性表达者(P=0.0115)。多元logistic回归分析显示,CD44v6阳性表达(P=0.048)和pTNM分期(P=0.035)对生存率有显著影响。结论肺癌中存在CD44v6过度表达,检测CD44v6的表达有助于预测肺癌患者的预后。
Background and objective Overexpression of CD44v6 is associated with occurrence, development and metastasis of a variety of human malignant tumors. The aim of this study is to determine the expression of CD44v6 and its prognostic significance in non-small cell lung cancer (NSCLC). Methods CD44v6 expression was detected in 52 NSCLC tissues and 12 normal pulmonary tissues by reverse transcription polyme-(rase) chain reaction (RT-PCR) and immunohistochemistry (SP method). Results The positive expression rate of CD44v6 was 69.2% (SP method) and 75.0% (RT-PCR method) in NSCLC, respectively. Significantly higher expression of CD44v6 was demonstrated in poorly differentiated tumors than that in moderately/well differentiated tumors (P<0.05). The expression of CD44v6 was remarkably higher in patients with lymphatic metastasis than that in those without lymphatic metastasis (P<0.01). CD44v6 expression in stage Ⅲ NSCLC was remarkably higher than that in stage Ⅰ and Ⅱ NSCLC (P<0.05). Survival rate of patients with negative CD44v6 expression was significantly higher than that of those with positive CD44v6 expression (P=(0.0115)). Multi-variate logistic analysis showed the expression of CD44v6 (P=0.048) and pTNM stage (P=0.035) were significantly prognostic factors. Conclusion Overexpression of CD44v6 is very common in lung cancer tissues. Detection of CD44v6 expression may be helpful to predict the prognosis of NSCLC patients.
出处
《中国肺癌杂志》
CAS
2005年第3期215-218,共4页
Chinese Journal of Lung Cancer
